Sign in
Taking people in United StatesPhase 4

Vonoprazan compared with usual acid medicine for acid reflux in Barrett's esophagus

Tests vonoprazan against usual acid-reducing pills in people with Barrett's esophagus.

Key facts

Who runs it
University of North Carolina, Chapel Hill
Where
Chapel Hill, United StatesSee the site
Trial code
Registry title
Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)
Status
Recruiting
Phase
Phase 4
People taking part
12 people, planned
Started
Nov 2026
Expected to end
31 Aug 2029
Type of study
Interventional
Treatments tested
  • Potassium-Competitive Acid Blockers (PCABs)
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Barrett's Esophagus without abnormal cell changes who take a PPI acid-reducing medicine daily. Participants switch from their PPI to the study drug Vonoprazan.

Age
18 years or older
Sex
All sexes
Disease stage
Barrett's Esophagus without dysplasia (no abnormal cell changes), segment length ≥2 cm (0.8 in), confirmed by endoscopy and tissue sample within the past 3 years. History of GERD (acid reflux), with or without heartburn.
Earlier treatment
Must be on PPI maintenance therapy once or twice daily for 3 or more months (90 days or more). People on twice daily PPI must be able to switch to once daily. No other acid-reducing medicines. No other study drug within 30 days.
Biomarker or test result
Tissue sample showing intestinal metaplasia without dysplasia.

Main reasons for not taking part

  • Barrett's Esophagus with dysplasia diagnosed within 12 months, or current or past esophageal cancer (EAC)
  • H. pylori diagnosis or treatment in the past 6 months
  • Past surgery on the upper digestive tract, such as for reflux
  • Cannot have the 24hr pH tube test, for example recent nose injury, bleeding problems, or a pacemaker or defibrillator
  • Pregnant, breastfeeding, or planning pregnancy or egg donation during the study and for 30 days after

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Adults aged 18 or older at time of consent
  • Able to read and understand English and provide written informed consent
  • History of Gastroesophageal Reflux Disease (GERD) with or without heartburn
  • Diagnosed with nondysplastic Barrett's Esophagus (NBDE) defined as meeting the following within the past 3 years:; Endoscopically confirmed BE with segment length ≥2 cm (to avoid those with an irregular Z line), and; Histologic evidence of intestinal metaplasia without dysplasia ("dysplasia" includes indefinite for dysplasia)
  • Currently on proton pump inhibitor (PPI) maintenance therapy, defined as PPI prescribed once or twice daily for 3 or more months (defined as 90 days or more) from consent. Any formulation and dosage of PPI will be included, including pantoprazole, omeprazole, esomeprazole, lansoprazole, rabeprazole, dexlansoprazole or their generic equivalents
  • If currently on twice daily PPI, then able to modify PPI regimen to once daily dosing as part of their routine clinical care
  • Ability to take oral medication and willing to adhere to study intervention regimen
  • Willing to follow lifestyle recommendations as outlined in protocol section 5.3

Who cannot take part

  • Current or prior esophageal adenocarcinoma (EAC)
  • Use of other acid suppressive medications
  • H. pylori diagnosis or treatment within the past 6 months prior to study entry
  • Treatment with another investigational product within 30 days prior to consent
  • Pregnant, breastfeeding, or considering becoming pregnant or intending to donate ova during the study and for 30 days after the last dose of study drug
  • History of upper gastrointestinal tract surgery (e.g., esophagectomy or surgery for reflux disease)
  • Current contraindication to 24hr pH impedance test, including:; Recent broken nose, nasal surgery, or known deviated septum; or; Bleeding disorders or those taking certain blood-thinning medications and unable to temporarily discontinue use per current clinical guidance may also be excluded due to increased risk of bleeding during catheter insertion; or; Individuals with implanted devices like pacemakers or defibrillators
  • Known hypersensitivity or allergic reaction to any component of the study intervention
  • Barrett's Esophagus (BE) with dysplasia (indefinite for dysplasia, or low-grade dysplasia, or high-grade dysplasia) diagnosed within 12 months of study entry
  • Current use of rilpivirine-containing products

Where in United States

  • University of North Carolina at Chapel HillChapel Hill, United StatesContact: Shilpa Karanjit, MPHTaking people

About the trial

What the trial wants to find out

This is a research study to look at how a new medication compares to standard treatment for reducing acid reflux in patients with Barrett's Esophagus. The study drug is Vonoprazan. This is a pill that is not yet FDA-approved for this purpose in this patient population.

Read full original descriptionShow less

The participants will first continue their current acid-reducing medicine (PPI) once a day for at least 7 days. After that, they will have a test to measure acid levels in their esophagus (food tube) while still taking the PPI medication. After this test, they will stop their current PPI medication and start taking the study drug, Vonoprazan, once a day for 7-28 days. They will then have a second acid test while on the study drug (Vonoprazan).

Before each test, the participants will complete a short questionnaire about their symptoms. The study team will collect their health history, including medical conditions and current medications. After they finish the study drug, they will have a follow-up visit in about 30 days. The participation in the study will then end.

The group in the trial

  • Proton Pump Inhibitors (PPI) to Potassium-Competitive Acid Blockers (PCABs)Other group

    All participants will be enrolled while receiving PPI. After participant has been on a once daily PPI therapry regimen for at least 7 days, a 24-hour ph impedance test will be conducted while still receiving PPI medication. Participants will then be switched to PCABs for 7-28 days. A second 24-hour ph impedance test will be conducted by Day 28 while participants are taking PCABs.

    Treatment: Potassium-Competitive Acid Blockers (PCABs)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)
Plain-language title
Vonoprazan compared with usual acid medicine for acid reflux in Barrett's esophagusGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
5 November 2026